influenza vaccine + GSK2604409A

influenza vaccine + GSK2604409A is an investigational vaccine combination consisting of an influenza antigen (such as H5N1 or H7N9) and the synthetic Toll-like receptor 4 (TLR4) agonist adjuvant GSK2604409A. Developed by GSK, this combination is designed to improve the magnitude and breadth of the immune response against influenza viruses, particularly in the context of pandemic preparedness. The adjuvant GSK2604409A acts by stimulating TLR4 on antigen-presenting cells, thereby enhancing the activation of the innate immune system and subsequent adaptive immunity. Clinical trials have evaluated this combination to determine if the addition of the synthetic TLR4 agonist allows for dose-sparing of the influenza antigen while maintaining protective immunogenicity.

Other names

TLR4a-adjuvanted influenza vaccineTLR-4a-adjuvanted influenza vaccineTLR 4a-adjuvanted influenza vaccinesynthetic TLR4 agonist-adjuvanted influenza vaccine